A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SKB445 for Injection in Patients with Advanced Solid Tumors
Latest Information Update: 21 Mar 2025
At a glance
- Drugs SKB 445 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Kelun Pharmaceutical Research Institute
Most Recent Events
- 17 Mar 2025 Status changed from not yet recruiting to recruiting.
- 21 Feb 2025 New trial record